Neurocrine Biosciences (NBIX) CLO Lippoldt Buys $799K of Stock
Chief Legal Officer Darin Lippoldt buys 9,800 shares of Neurocrine Biosciences, valued at nearly $800,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, Inc. ($NBIX), bought 9,800 shares at an average price of $81.49, worth about $798,602, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NBIX is up 2.4% after 1 week, up 6.3% after 1 month and down 20.2% to date (from the $170 close on Jun 29, 2026).
NBIX
Neurocrine Biosciences, Inc.
Key Points
- Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, bought 9,800 shares for about $798,602 on June 29, 2026, at a price of $81.49 each.
- The stock is currently trading around $170, significantly above its 52-week low of $122.14.
- Analysts have a 'strong buy' consensus on Neurocrine with a target mean price of $208.40.
Get $NBIX trade alerts by text
We text you when insiders, Congress or big funds trade $NBIX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neurocrine Biosciences, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Neurocrine Biosciences, Inc.
Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, Inc. (NBIX), made a significant purchase of 9,800 shares on June 29, 2026. This trade was valued at approximately $798,602, buying each share at $81.49. This investment reflects Lippoldt’s confidence in the company’s future prospects as it operates in the healthcare sector, particularly focusing on pharmaceutical development for neurological and psychiatric disorders.
Recent Activity by Lippoldt
This recent purchase is Lippoldt's third notable buying activity within a week. Just a few days earlier, on June 26, 2026, he bought 200 shares on two separate occasions, each valued at $16,298. These consistent purchases may signal strong personal confidence in the company's direction and performance.
Analysts Set New Price Targets
Analysts maintain a positive outlook on Neurocrine Biosciences. On October 16, 2026, Needham reiterated a 'Buy' rating with a price target of $204. Similarly, UBS, on September 29, 2026, maintained a 'Buy' rating with a target of $214. These recommendations add to a consensus that suggests robust potential for the stock, which is currently trading well above its 200-day moving average of $147.90.
Stock Performance Overview
Neurocrine's stock is trading around $170, significantly above its 52-week low of $122.14 and near its high of $186.12. This trading range indicates strong market performance and investor interest. The stock's current position reflects confidence, especially with upcoming earnings expected on October 28, 2026.
What NBIX Does
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals targeting neurological, psychiatric, and endocrine disorders. The company is known for its products like INGREZZA, used for treating tardive dyskinesia, and others that focus on various health conditions. As it approaches its next earnings report, investor sentiment appears optimistic, driven by both insider purchases and analyst support.
What's Ahead for NBIX
With the next earnings report scheduled for October 28, 2026, investors will be paying close attention to how the company performs and any updates on its product pipeline. Lippoldt's recent insider buying may suggest he expects positive developments in the near future. As always, it's important to remember that the recent trades reflect positions at the time of filing and may not represent current holdings.
Related Filing Alerts
Source: Darin Lippoldt's Form 4 filing on $NBIX (Jun 29, 2026). Find the original filing: NBIX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts